Enigma Biomedical USA Announces FDA Approval of TAUKLARIFY™ (florquinitau F 18 injection) for Use in Patients Being Evaluated for Alzheimer’s Disease

A novel diagnostic agent to identify patients with tau neurofibrillary tangles (NFTs), including NFTs isolated to the medial temporal lobe KNOXVILLE, Tenn. — Enigma Biomedical USA (EB USA) today announced the U.S. Food and Drug Administration (FDA) approval of TAUKLARIFY™ (florquinitau F 18 injection, also previously referred to as MK-6240), a radiodiagnostic agent indicated for […]